We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
12 own
9 watching
Current Price
$50.77
$-1.48
(-2.83%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
9,138.6M
52-Week High
130.97
52-Week Low
40.69
Average Volume
2.63M
Dividend Yield
--
P/E Ratio
38.4575
Market Capitalization9,138.6M
52-Week High130.97
52-Week Low40.69
Average Volume2.63M
Dividend Yield--
P/E Ratio38.4575
What does the Stockal+Disclaimer.pdf do?
Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for softgels, which are used in a range of customer products, including prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics. Its principal softgel technologies include traditional softgel capsules, and Vegicaps and OptiShell capsules. The Drug Delivery Solutions segment formulates, develops, and manufactures prescription, and consumer and animal health products using proprietary technologies, including OptiMelt, OptiPact, OptiForm, and Zydis, as well as other proprietary and conventional drug delivery technologies, such as prefilled syringes; manufactures blow-fill seal unit dose, including ADVASEPT technology; develops biologic cell line, including GPEx and SMARTag technologies; and provides analytical and bioanalytical development, and testing services, as well as offers respiratory products formulation and manufacturing, micronization and particle engineering, and regulatory consulting services. The Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials for customer required patient kits. This segment also offers FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical and biotechnology companies; and consumer health companies, as well as companies in other healthcare market segments, such as animal health and medical devices, and companies in industries, including cosmetics. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
18days ago
Shares of Catalent, Inc. (NYSE:CTLT Get Rating) have been assigned a consensus recommendation of Hold from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and ...
Ticker Report
27days ago
Catalent, Inc. (NYSE:CTLT Get Rating) Equities research analysts at William Blair reduced their Q2 2023 earnings per share (EPS) estimates for Catalent in a report issued on Wednesday, November 2nd. William Blair analyst M. Smock now forecasts that the company will earn $0.53 per ...
Zolmax
28days ago
Catalent, Inc. (NYSE:CTLT Get Rating) Research analysts at William Blair reduced their Q2 2023 EPS estimates for Catalent in a research note issued to investors on Wednesday, November 2nd. William Blair analyst M. Smock now forecasts that the company will earn $0.53 per share for the quarter, down ...
Zolmax
1month ago
Catalent (NYSE:CTLT Get Rating) had its price target dropped by Royal Bank of Canada from $125.00 to $73.00 in a report released on Wednesday, The Fly reports. The brokerage currently has an outperform rating on the stock. Royal Bank of Canadas target price indicates a ...
Ticker Report
1month ago
Yousif Capital Management LLC increased its holdings in Catalent, Inc. (NYSE:CTLT Get Rating) by 1.9% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 25,021 shares of the companys stock after buying an additional 460 shares during...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$50.77
$-1.48
(-2.83%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00